Drug Profile

Research programme: cancer therapeutics - HK inno.N

Alternative Names: CJ-12537; IN-A005; IN-A007

Latest Information Update: 21 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CJ Cheiljedang Corp.
Developer HK inno.N
Class Antineoplastics; Small molecules
Mechanism of Action Adenosine A2A receptor antagonists; DCLK1 protein inhibitors; Protein tyrosine phosphatase non receptor type 1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Jan 2022 Preclinical trials in Cancer in South Korea (unspecified route) (HK inno.N pipeline, January 2022)
29 Jul 2020 Early research development is ongoing in South Korea
18 Jun 2020 CJ HealthCare is now called HK inno.N

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com